Nuvalent (NUVL) Total Non-Current Liabilities (2024 - 2026)
Nuvalent (NUVL) posted Total Non-Current Liabilities of $156.8 million for Q1 2026, down 4.59% on a QoQ basis from $164.3 million in Q4 2025, and up 66.07% year-over-year from $94.4 million in Q1 2025.
Nuvalent (NUVL) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends
Nuvalent's Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $156.8 million for Q1 2026.
- Quarterly Total Non-Current Liabilities rose 66.07% year-over-year to $156.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156.8 million (up 66.07% YoY) and the FY2025 annual result came in at $164.3 million, up 128.36% from the prior year.
- Total Non-Current Liabilities was $156.8 million for Q1 2026 at Nuvalent, down from $164.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $164.3 million in Q4 2025 and bottomed at $51.1 million in Q3 2024.
- A 3-year average of $110.5 million and a median of $100.6 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Non-Current Liabilities surged 162.79% — and 2026, when it jumped 66.07%.
- Nuvalent's Total Non-Current Liabilities stood at $72.0 million in 2024, then jumped by 128.36% to $164.3 million in 2025, then slipped by 4.59% to $156.8 million in 2026.
- Business Quant data shows NUVL's Total Non-Current Liabilities at $156.8 million in Q1 2026, $164.3 million in Q4 2025, and $134.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 156.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 156.78 Mn |
| Dec 31, 2025 | 164.33 Mn |
| Sep 30, 2025 | 134.37 Mn |
| Jun 30, 2025 | 100.56 Mn |
| Mar 31, 2025 | 94.40 Mn |
| Dec 31, 2024 | 71.96 Mn |
| Sep 30, 2024 | 51.13 Mn |